OBJECTIVES:   Fingolimod 0.5mg daily has been registered in France in 2011 indicated in patients with highly active relapsing-remitting multiple sclerosis (RRMS). The objective of this economic analysis is to assess the evolution of health resources consumptions of patients treated with fingolimod at 12 months follow up from a payer’s perspective. METHODS:   Health resources consumptions data were extracted from the largest study in France to date evaluating fingolimod in real-world settings, a non-interventional, multicentre, and observational study including patients treated with fingolimod, with prospective follow up for 3 years. Besides efficacy and safety, endpoints include quality of life and health resource consumptions collected through patient questionnaires. The costs for health resources valorization were estimated from the payer’s perspectives, using healthcare system databases. Mean hospitalizations costs were calculated using DRG rates for patients presenting with MS as main, associated or related diagnosis.  RESULTS: A total of 1011 patients treated with fingolimod were enrolled in the study. At 12 months follow up, results confirm the efficacy and safety profile of fingolimod. Disability was stable and quality of life was maintained with a stable utility scores of 0.7 (EQ5D). Health resource consumption was decreased. In patients treated with fingolimod, hospitalizations were reduced by 80% and the proportion of patients with sick leave decreased by 47%, leading to a mean cost decrease per patient of -510€ and -464€, respectively. GP consultations were reduced by 13% and neurologist consultations by 34%. CONCLUSIONS: The one year data analysis from this study evaluating fingolimod in real-world settings shows a reduction in health resource consumption and confirms long-term efficacy and safety profile of fingolimod with a maintained quality of life.